PDCD1 and neoplasm: Although PD-1 blockade is a known therapy to activate tumor-infiltrating T cells, emerging evidence has shown that TILC2s also benefit from anti-PD-1 antibody, activating their ability to carry out anti-tumor responses [60,62].